New York A 6927: Relates to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
A06927 Summary:

BILL NOA06927A

&nbsp

SAME ASSAME AS S10466

&nbsp

SPONSORSimone

&nbsp

COSPNSRTapia, Epstein, Gonzalez-Rojas, Reyes, Shimsky, Glick, Schiavoni, Lunsford, Romero, Meeks, Bronson,
 Seawright, Hevesi, Simon, Rosenthal, Raga, Lee, Wright, Levenberg, Kelles

&nbsp

MLTSPNSR

&nbsp

Amd §§6807 & 6810, Ed L; amd §280-d, Pub Health L

&nbsp

Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.

Go to top A06927 Actions:

BILL NOA06927A

&nbsp

03/18/2025referred to higher education

01/07/2026referred to higher education

05/28/2026amend (t) and recommit to higher education

05/28/2026print number 6927a

Go to topA06927 Committee&nbspVotes:

Go to topA06927 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topA06927 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 6927--A

 2025-2026 Regular Sessions

 IN ASSEMBLY

 March 18, 2025
 ___________

 Introduced by M. of A. SIMONE, TAPIA, GONZALEZ-ROJAS, REYES, SHIMSKY,
 GLICK, SCHIAVONI, LUNSFORD, ROMERO, MEEKS, BRONSON, SEAWRIGHT, HEVESI,
 SIMON, ROSENTHAL, RAGA, LEE, WRIGHT, LEVENBERG, KELLES -- read once
 and referred to the Committee on Higher Education -- recommitted to
 the Committee on Higher Education in accordance with Assembly Rule 3,
 sec. 2 -- committee discharged, bill amended, ordered reprinted as
 amended and recommitted to said committee

 AN ACT to amend the education law and the public health law, in relation
 to prescription labels for gonadotropin-releasing hormone agonists,
 pubertal suppressants, anabolic steroids, alpha reductase inhibitors,
 progestins, or drug classes for hormone replacement therapy for treat-
 ment of gender dysphoria

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. Paragraph b-1 of subdivision 1 of section 6807 of the
 2 education law, as amended by chapter 108 of the laws of 2025, is amended
 3 to read as follows:
 4 b-1. Notwithstanding paragraph b of this [section] subdivision, the
 5 prescription label for mifepristone [or], misoprostol, gonadotropin-re-
 6 leasing hormone agonists, pubertal suppressants, anabolic steroids,
 7 alpha reductase inhibitors, progestins, or drug classes for hormone
 8 replacement therapy for treatment of gender dysphoria, may include the
 9 name or address of the dispensing health care practice instead of the
 10 name of the dispenser.
 11 § 2. Subdivision 1-a of section 6810 of the education law, as amended
 12 by chapter 108 of the laws of 2025, is amended to read as follows:
 13 1-a. Notwithstanding subdivision one of this section, at the
 14 prescriber's request, the prescription label for mifepristone [or],
 15 misoprostol, gonadotropin-releasing hormone agonists, pubertal suppres-
 16 sants, anabolic steroids, alpha reductase inhibitors, progestins, or
 17 drug classes for hormone replacement therapy for treatment of gender

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD10852-03-6

 A. 6927--A 2

 1 dysphoria, shall include the name or address of the prescribing health
 2 care practice instead of the name of the prescriber.
 3 § 3. Section 280-d of the public health law, as added by chapter 108
 4 of the laws of 2025, is amended to read as follows:
 5 § 280-d. Patient notification of prescription label change. A health
 6 care prescriber shall inform the patient if such prescriber has included
 7 or has requested to include the name or address of the prescribing
 8 health care practice instead of the name of such prescriber on the
 9 prescription label when prescribing mifepristone [or], misoprostol,
 10 gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic
 11 steroids, alpha reductase inhibitors, progestins, or drug classes for
 12 hormone replacement therapy for treatment of gender dysphoria.
 13 § 4. This act shall take effect immediately.

Go to top 

• 

 Sitemap 

 Request Information 

 Directions and Maps